Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.

Thoracic Cancer
Takayuki KishikawaMasafumi Sata

Abstract

Osimertinib is recommended for T790M mutation-positive advanced non-small cell lung cancer (NSCLC) resistant to first- and second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs). Recently, some reports exist on the real-world use of osimertinib; however, reports involving third/later-line use are few. Hence, this study was conducted to evaluate the efficacy and safety of osimertinib used in various treatment lines for T790M-positive NSCLC patients. This retrospective, observational, multicenter study included T790M-positive advanced/recurrent NSCLC patients treated with osimertinib from May 2016 to March 2018. The clinical characteristics, efficacy, and adverse events were retrospectively investigated. The Kaplan-Meier method was used to analyze progression-free survival (PFS) and overall survival (OS). PFS-associated clinical characteristics were evaluated using the Cox proportional hazards model. The objective response rate (ORR) and disease control rate (DCR) were 60.7% and 91.1%, respectively; the median PFS was 11.0 months. There were no significant differences in the median PFS for patients treated with osimertinib as second-line and third-/later-line (14.5 vs. 11.0 months respectively...Continue Reading

References

Aug 28, 2007·International Journal of Occupational and Environmental Health·Yvonne KohlhammerJoachim Heinrich
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Jan 27, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Katsuyuki HottaMitsune Tanimoto
Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Apr 17, 2012·Journal of the American Academy of Dermatology·Alice P ChenMario E Lacouture
Jul 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lecia V SequistMartin Schuler
Mar 5, 2014·European Respiratory Review : an Official Journal of the European Respiratory Society·Martin SebastianMartin Reck
Feb 6, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Caicun Zhou, Luan Di Yao
Sep 8, 2016·Investigational New Drugs·Nobuaki MamesayaToshiaki Takahashi
Dec 14, 2016·The New England Journal of Medicine·Tony S MokUNKNOWN AURA3 Investigators
Dec 21, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M KotakeT Takahashi
Feb 22, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James Chih-Hsin YangPasi A Jänne
Nov 21, 2017·The New England Journal of Medicine·Jean-Charles SoriaUNKNOWN FLAURA Investigators
Feb 28, 2018·Critical Reviews in Oncology/hematology·Chiara TomaselloStefano Cascinu
Jul 15, 2018·Journal of the National Comprehensive Cancer Network : JNCCN·David S EttingerMiranda Hughes

❮ Previous
Next ❯

Software Mentioned

R Commander
EZR
R

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.